Introduction
============

Parathyroid hormone (PTH) plays a critical role in maintaining adequate serum calcium homeostasis. It increases serum calcium by stimulating bone resorption, promoting phosphate excretion, converting vitamin D to its active form and by limiting calcium excretion. The PTH molecule can be oxidised at methionine residues 8 and 18 ([@bib1]). This results in an inability to activate the PTH-1 receptor, rendering the hormone biologically inactive ([@bib1], [@bib2], [@bib3], [@bib4]). The oxidation of PTH occurs only *in vivo* and does not progress after blood withdrawal ([@bib5]).

Over the past decades, PTH assays have improved greatly. The first-generation PTH assays were radioimmunoassays and used a single antibody to quantify PTH levels in the blood. However, these assays measured not only intact PTH, but also PTH fragments with no biological activity. Subsequently, a second-generation immunoassay was developed, using the sandwich principle with two antibodies directed close to the C- and N-terminal parts. This resulted in a major improvement in diagnostic and prognostic use of PTH measurements. A third-generation assay captured the full-length PTH and had antibodies detected against the most proximal and distal binding sites of the hormone ([@bib6]). There is still an ongoing debate on whether these third-generation assays have additional value compared to the second-generation assays. However, not only fragmentation, but also the above-mentioned posttranslational oxidation of PTH can affect the measurements ([@bib7]). The inactive oxidised PTH (oxPTH) cross-reacts in the frequently used PTH immunoassays ([@bib3], [@bib4]). Therefore, the assumption that the PTH measured by the third generation is biologically active PTH, is probably not the case, as this assay measured both the oxidised or non-oxidised PTH.

A newly developed method enables measurement of solely the non-oxidised fraction of PTH ([@bib8]). This non-oxidised PTH (n-oxPTH) can be measured by automated immunoassays in the eluate which remains after removal of oxidised PTH by using an oxPTH affinity column.

As only n-oxPTH activates the PTH-1 receptor, it may reflect the hormonal function of PTH better than the currently measured PTH, which is a combination of oxidised and non-oxidised PTH. As a large fraction of circulating PTH is oxidised, this total PTH (tPTH) may rather reflect oxidative stress-related pathology ([@bib9]). Tepel *et al.* showed that haemodialysis patients with higher n-oxPTH concentrations had an increased survival. Per contra, tPTH is associated with mortality in both chronic kidney disease patients and in healthy individuals ([@bib10], [@bib11]). In addition, Seiler-Mussler *et al.* recently concluded that currently measured PTH is associated with all-cause mortality, in contrast to n-oxPTH in chronic kidney disease ([@bib12]). This opposite relationship supports the rationale that n-oxPTH may reflect the hormonal status more accurately.

PTH secretion is suppressed by 1,25(OH)~2~Vitamin D and to a lesser extent by 25(OH)Vitamin D (25(OH)D) ([@bib13]). Hence, 25(OH)D deficiency leads to increased PTH levels in order to prevent deranging calcium homeostasis. Conversely, PTH secretion is diminished after vitamin D supplementation.

In this study, we aimed to investigate the effect of vitamin D supplementation on the n-oxPTH concentrations in comparison to tPTH in a population with normal renal function. For this purpose, we measured n-oxPTH in the Styrian Hypertension Study, a vitamin D randomised controlled trial ([@bib14]). In addition, we investigated the relationship between bone resorption and formation markers, markers of lipid metabolism and parameters of mineral metabolism and oxidative stress with n-oxPTH and tPTH.

Subjects and methods
====================

Study design and participants
-----------------------------

Samples from the Styrian Vitamin D Hypertension Trial, a single-centre, double-blind, placebo-controlled, parallel-group study performed at the Medical University of Graz, Austria (NCT02136771; ClinicalTrials.gov), with sufficient material for n-oxPTH measurements were used ([@bib14]).

The participants were aged 18 years or older, were diagnosed with arterial hypertension and had 25(OH)D concentrations \<75 nmol/L (according to the assay used in the trial: IDS-iSYS 25-hydroxyvitamin assay; Immunodiagnostic Systems Ltd., Boldon, UK). Arterial hypertension was defined as an office blood pressure of systolic ≥140 mmHg or diastolic ≥90 mmHg, a mean 24-h ambulatory blood pressure monitoring of systolic ≥125 mmHg or diastolic ≥80 mmHg, a home blood pressure of systolic ≥130 mmHg or diastolic ≥85 mmHg or ongoing antihypertensive treatment. For study details, we refer to the article published by Pilz *et al.* ([@bib14]). Exclusion criteria included hypercalcaemia, an estimated glomerular filtration rate \<15 mL/min per 1.73 m^2^, a regular intake of \>880 IU of vitamin D daily during the last 4 weeks in addition to the study medication, 24-h systolic blood pressure \>160 mmHg or \<120 mmHg, 24-h diastolic blood pressure \>100 mmHg, pregnant or lactating women, acute coronary syndrome, cerebrovascular events within the previous 2 weeks, diseases with an estimated life expectancy of less than 1 year, any clinically significant acute disease requiring drug treatment, chemotherapy or radiation therapy and a change in antihypertensive treatment during the previous 4 weeks or planned change of antihypertensive treatment.

Written informed consent was obtained from all study participants. The study was approved by the Ethics Committee of the Medical University of Graz, Austria and was designed to comply with the Declaration of Helsinki.

Intervention
------------

Eligible participants were randomly assigned to receive either 2800 IU of vitamin D~3~ (Oleovit D~3~, Fresenius Kabi Austria, Austria) or a matching placebo administered orally by seven oily drops per day for 8 weeks. Randomisation was carried out using Web-based randomisation software (Randomizer). All investigators and authors enrolling participants, collecting data and assigning intervention were masked to participant allocation. The study took place between June 2011 and August 2014. Detailed information was published previously ([@bib14]).

Outcome measures
----------------

In this *post hoc* study analysis, we aimed to investigate the effects of vitamin D supplementation on tPTH and n-oxPTH concentrations between groups, adjusted for baseline values. In addition, we studied the correlation between n-oxPTH, tPTH concentrations, markers of bone turnover, lipid metabolism, calcium and phosphate homeostasis and asymmetric dimethylarginine (ADMA), a downstream marker of oxidative stress

Biochemical analysis
--------------------

EDTA plasma samples were obtained after an overnight fast and were centrifuged and stored at −80°C until determination. 25(OH)D~3~ was assessed by isotope dilution liquid chromatography-tandem mass spectrometry at the Endocrine Laboratory of the VU University Medical Center, as described previously ([@bib15]). The limit of quantitation was 1.2 nmol/L and the intra- and inter-assay variation (CV) was 3 and 6%, respectively. PTH concentration was measured in EDTA plasma using an automated second-generation PTH immunoassay (Elecsys, Roche Diagnostics) with an intra- and inter-assay CV of \<2.7 and \<6.5%, respectively. N-oxPTH concentration was determined using an oxPTH affinity column (A1112; Immundiagnostik AG, Bensheim, Germany). These affinity columns are filled with an antibody containing slurry that specifically binds the oxidised form of PTH and after being centrifuged, the eluate contains only the non-oxidised form of PTH ([@bib8]). The columns were filled with 300 μL EDTA plasma and incubated end-over-end at room temperature for 1 h. Afterwards, we determined n-oxPTH in the eluate using a second-generation PTH immunoassay (Elecsys, Roche Diagnostics). Combined with use of the n-oxPTH columns the inter-assay CV \<2 pmol/L and \>2 pmol/L is 10 and 2.4%, respectively ([@bib5]).

Total osteocalcin (OC), a bone formation marker, was measured by an electrochemiluminescence immunoassay (Elecsys, Roche Diagnostics). The intra- and inter-assay CV was 0.5 and 1.4%, respectively. CTX, a bone resorption marker, was measured by electrochemiluminescence immunoassay (Elecsys, Roche Diagnostics). The intra- and inter-assay CV was 2.0 and 4.2%, respectively. Concentrations of bone-specific alkaline phosphatase, also a marker of bone formation (bALP; inter-assay CV: 5.2%), were determined by a spectrophotometric immunoassay (IDS-ISYS Ostase BAP; Immunodiagnostic Systems Ltd. (IDS Ltd.), Boldon, Tyne & Wear, UK). Procollagen type 1 amino-terminal propeptide (P1NP), also a bone formation marker, was measured by an automated electrochemiluminescence immunoassay (Elecsys, Roche Diagnostics) with an inter-assay CV of 2.7%. To measure 1,25(OH)~2~D~3~, a chemiluminescence immunoassay (IDS-iSYS 1,25VitDXp; Immunodiagnostic Systems Ltd., Boldon, UK) was used, of which the intra- and inter-assay CV was 6.4--12.1% and 6.6--9.6%, respectively. Vitamin D-binding protein was measured by the Quantikine Human Vitamin D-Binding Protein immunoassay (R&D Systems, Inc.). Intra- and inter-assay coefficients of variation were \<5.1 and \<7.4%, respectively. FGF23 was measured by a multi-matrix ELISA (FGF23 (C-terminal) ELISA; Biomedica Medizinprodukte GmbH & CO KG, Vienna, Austria). The intra-assay and inter-assay coefficients of variation (CVs) were ≤12 and ≤10%, respectively. The effect of vitamin D supplementation on bone turnover markers and FGF23 in this cohort was published previously ([@bib16], [@bib17]). Total cholesterol, HDL and triglycerides were measured using an enzymatic colorimetric assay (Elecsys, Roche Diagnostics). LDL was calculated according to the Friedewald equation. Asymmetric dimethylarginine (ADMA), a downstream marker of oxidative stress, was measured with reversed-phase HPLC ([@bib18]). Assay specifications and the effect of vitamin D supplementation on ADMA in this cohort were published previously ([@bib19]).

Statistical analysis
--------------------

Data following a normal distribution are shown as means with standard deviation ([s.d.]{.smallcaps}), data following a skewed distribution are shown as medians with interquartile ranges. Skewed variables were log transformed prior to parametric analyses. At baseline, the Mann--Whitney *U* test was used to assess the differences between the vitamin D-treated group and placebo-treated group. In order to compare the decrease in n-oxPTH with the decrease in tPTH, the Mann--Whitney *U* test was also used between the percentage differences. Pearson's and Spearman's correlation coefficients were used to evaluate the relationship between baseline parameters, n-oxPTH and tPTH. Spearman's correlation coefficient was used when skewed variables were not normally distributed after log transformation. In addition, Spearman's correlation coefficient was used to assess the correlation between the change, calculated as the difference between the parameter measured at the final study visit and the same parameter at the baseline study visit, in n-oxPTH, tPTH and the n-oxPTH/tPTH ratio and several parameters in the vitamin D-treated group. These calculated changes are marked with '∆'. Also, Bonferroni corrected values were reported. Analysis of covariance (ANCOVA) with adjustment for baseline values was used to test for differences in the outcome variables (i.e. 25(OH)D~3~, n-oxPTH, tPTH, plasma calcium, 24-h calcium excretion, 1,25OH~2~D, biologically available 25(OH)D~3~, the n-oxPTH/tPTH ratio and ADMA). Values more than 3SD from the mean were deemed as outliers, they were removed and the analysis repeated. This is marked in the results section. Biologically available 25(OH)D~3~ was calculated using equations adapted from Vermeulen *et al.* ([@bib20]). For the adapted formula and an example of the calculation of bioavailable 25(OH)D, we refer to the supplement of Powe *et al.* ([@bib21]). The percentage change of a given parameter in the vitamin D-treated group was calculated by dividing the change from baseline after treatment by its respective baseline value.

A *P* value \<0.05 was considered statistically significant. All analyses were performed using SPSS version 22 (SPSS).

Results
=======

The trial was completed by 188 participants; the participant flow chart was published previously ([@bib14]). For the current study, we included 108 participants (53 in treatment group and 55 in placebo group) of which sufficient material was present for n-oxPTH measurement at baseline and follow-up. The baseline characteristics of the included patients are shown in [Table 1](#tbl1){ref-type="table"}. There was no significant difference between the vitamin D- and placebo-treated group at baseline. Table 1Baseline characteristics of participants in the vitamin D (*n* = 53) and placebo (*n* = 55)-treated groups.ParametersAll*N*Vitamin D*N*Placebo*NP* valueAge (years)60.1 ± 11.910859.5 ± 11.85360.7 ± 12.1550.384Gender (% female)60108295331550.863% postmenopausal females4759242923300.561BMI (kg/m^2^)30.0 ± 5.310730.3 ± 4.95329.7 ± 5.8540.50125(OH)D~3~ (nmol/L)46 (25--58)10746 (37--58)5246 (30--59)540.5381,25(OH)~2~D (pg/mL)48 (35--65)10749 (38--66)5342 (29--64)540.153Vitamin D binding protein (μg/mL)249 ± 110107237 ± 10853258 ± 112540.355Bioavailable 25(OH)D~3~ (nmol/L)5.80 (3.76--8.13)1066.60 (4.10--8.03)525.15 (3.20--8.47)540.123Serum calcium (mmol/L)2.26 (2.21--2.33)1082.26 (2.21--2.33)532.26 (2.21--2.33)550.824Serum phosphate (mmol/L)0.94 ± 0.171080.92 ± 0.16530.96 ± 0.17550.19924 h urinary calcium excretion (mmol/24 h)3.34 (1.85--5.01)973.63 (1.88--6.23)482.96 (1.85--4.86)490.325N-oxPTH (pmol/L)1.1 ± 0.31081.1 ± 0.3531.1 ± 0.3550.340Total PTH (pmol/L)5.3 (4.0--6.7)1085.2 (4.1--6.7)535.5 (3.9--6.8)550.710bALP (μg/L)17 (13--21)10317 (13--21)5117 (13--20)520.962CTX (ng/mL)0.19 (0.11--0.33)1000.19 (0.13--0.34)500.18 (0.10--0.28)500.647Osteocalcin (ng/mL)13 (10--19)10613 (10--18)5214 (9--19)540.859P1NP (ng/mL)38 (31--52)10338 (29--56)5038 (32--49)530.879eGFR CKD-EPI (mL/min/1.73 m^2^)83 ± 1910885 ± 185381 ± 19550.336FGF23 (pmol/L)0.83 (0.59--1.24)1070.77 (0.54--1.17)530.89 (0.69--2.02)540.069Office systolic BP\* (mmHg)145 ± 16107145 ± 1753145 ± 16540.856Office diastolic BP\* (mmHg)87 ± 1110787 ± 105387 ± 11540.981Ratio n-oxPTH/tPTH0.22 ± 0.071080.22 ± 0.07530.22 ± 0.06550.850Total cholesterol (mg/dL)192 ± 40108198 ± 3953186 ± 40550.104HDL (mg/dL)55.5 (47--66)10854.0 (45--66)5356.0 (47--66)550.612LDL (mg/dL)112 ± 35105117 ± 3353107 ± 37520.137Triglycerides (mg/dL)110 (69--153)108109 (69--152)53110 (69--162)550.996ADMA (μmol/L)0.70 (0.63--0.78)1080.69 (0.63--0.78)530.71 (0.64--0.79)550.247[^2][^3]

Cross-sectional analysis
------------------------

The Pearson correlation coefficients between n-oxPTH, tPTH, bone formation markers (bALP, osteocalcin, P1NP), a bone resorption marker (CTX) and FGF23 are shown in [Table 2](#tbl2){ref-type="table"}. Spearman correlation analysis for assessing non-linear relationships are shown in Supplementary Table 1 and Supplementary Table 2 (see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article); these did not considerably differ from the results of the Pearson correlation analysis. tPTH and n-oxPTH showed a significant correlation (*r* = 0.555; *P* \< 0.001; [Fig. 1](#fig1){ref-type="fig"}). Bone formation or resorption markers and FGF23 did not exhibit a significant correlation with either tPTH or n-oxPTH at baseline after Bonferroni adjustment. [Table 2](#tbl2){ref-type="table"} also displays that total cholesterol, HDL, LDL and triglycerides showed no significant correlation with n-oxPTH or tPTH after Bonferroni adjustment. Figure 1Scatterplot of tPTH and n-oxPTH at baseline (*n* = 108). Pearson's *r* = 0.555; *P* \< 0.001. Table 2Correlations between bone turnover parameters, parameters of lipid metabolism and n-oxPTH or tPTH.Parametersn-oxPTHTotal PTH\*Pearson's *rP* valueBonferroni adjusted *P* valuePearson's *rP* valueBonferroni adjusted *P* valueTotal PTH\*0.555\<0.001\<0.001n.a.n.a.n.a.bALP\*0.1440.1481.0000.0240.8131.000CTX\*−0.0280.7831.000−0.0600.5521.000Osteocalcin\*0.2370.0140.2520.1080.2681.000P1NP\*0.1690.0881.000−0.0290.7741.000FGF23\*−0.0160.8691.0000.0100.9161.000Total cholesterol−0.0470.6251.0000.0080.9341.000HDL\*0.2540.0080.1440.1660.0851.000LDL−0.0890.3651.000−0.0210.8311.000Triglycerides\*−0.2160.0250.450−0.0420.6661.000[^4]

The relationship between mineral metabolism markers, ADMA and vitamin D and tPTH and n-oxPTH is shown in [Table 3](#tbl3){ref-type="table"}. After Bonferroni correction, none of the tested parameters showed a significant correlation. Table 3Correlations between parameters of calcium and phosphate homeostasis, ADMA and n-oxPTH or tPTH.Parametersn-oxPTHTotal PTH\*Pearson's *rP* valueBonferroni adjusted *P* valuePearson's *rP* valueBonferroni adjusted *P* value25(OH)D~3~\*−0.0690.4771.000−0.0560.5641.000Bioavailable 25(OH)D~3~\*−0.0620.5261.000−0.1110.2581.0001,25(OH)~2~D\*0.1790.0651.0000.2150.0260.572eGFR0.0800.4101.000−0.0630.5191.000Calcium−0.0530.5881.0000.0080.9351.000Phosphate−0.1140.2391.000−0.2130.0270.594UPCR0.0880.3631.0000.1830.0591.00024-h urinary calcium^†^0.0630.5421.000−0.1270.2161.000ADMA\*−0.1040.2851.0000.0170.8611.000[^5][^6]

Interventional analysis
-----------------------

After vitamin D treatment, ANCOVA analysis revealed for 25(OH)D~3~ concentrations a mean treatment effect (95 % CI) of 32.4 nmol/L (25.9--38.8); *P* \< 0.001. This can be seen in [Table 4](#tbl4){ref-type="table"}. Biologically available 25(OH)D also increased compared to the placebo group (treatment effect: 3.91 nmol/L (2.64--5.18); *P* \< 0.001). Both tPTH and n-oxPTH decreased after vitamin D treatment (−0.90 (−0.40 to −1.40) pmol/L; *P* \< 0.001; and −0.08 (−0.01 to −0.15) pmol/L; *P* = 0.025, respectively). The decrease in tPTH and n-oxPTH (9 and 7%, respectively) was not significantly different (*P* = 0.51). The ratio of n-oxPTH/tPTH showed a trend for increase after vitamin D treatment (0.022 (0.003--0.042); *P* = 0.027 or expressed as percentage by 2.2% (0.3--4.2%)) In addition, 1,25(OH)~2~D concentrations increased after treatment (10.6 pg/mL (3.94--17.2); *P* = 0.002), while plasma calcium concentrations and 24-h urinary calcium excretion were not affected. ADMA did not show a significant treatment effect after vitamin D supplementation. Table 4ANCOVA for the effect of vitamin D or placebo treatment.ParametersGroupBaseline (SD/IQR)Follow-up (SD/IQR)Mean change (95% CI)Treatment effect (95% CI)*P* value25(OH)D~3~ (nmol/L)Vitamin D, *N* = 5249.0 ± 18.179.3 ± 19.130.3 (24.1--36.4)32.4 (25.9--38.8)\<0.001Placebo, *N* = 5446.0 ± 18.545.3 ± 19.7−0.72 (−4.77 to 3.32)Total PTH (pmol/L)\*Vitamin D, *N* = 535.19 (4.13--6.69)4.64 (3.90--5.80)−0.61 (−0.96 to −0.27)−0.90 (−0.40 to −1.40)\<0.001Placebo, *N* = 555.46 (3.92--6.66)5.33 (4.07--7.07)0.35 (−0.03 to 0.74)n-oxPTH (pmol/L)Vitamin D, *N* = 531.1 ± 0.31.1 ± 0.3−0.08 (−0.13 to −0.03)−0.08 (−0.01 to −0.15)0.025Placebo, *N* = 551.1 ± 0.31.1 ± 0.30.01 (−0.04 to 0.07)Plasma calcium (mmol/L)Vitamin D, *N* = 532.28 ± 0.102.27 ± 0.09−0.01 (−0.03 to 0.02)0.02 (−0.01 to 0.05)0.294Placebo, *N* = 552.27 ± 0.112.25 ± 0.11−0.01 (−0.03 to 0.01)24-h urinary calcium excretion (mmol/24 h)\*Vitamin D, *N* = 373.60 (1.45--6.25)3.80 (1.80--6.40)0.43 (−0.14 to 1.00)0.66 (−0.07 to 1.39)0.077Placebo, *N* = 402.95 (1.90--5.40)3.00 (1.50--4.60)−0.19 (−0.67 to 0.29)1,25(OH)~2~D (pg/mL)Vitamin D, *N* = 5353.5 ± 20.960.2 ± 25.16.66 (1.06--12.3)10.6 (3.94--17.2)0.002Placebo, *N* = 5347.0 ± 20.945.3 ± 15.9−1.12 (−5.84 to 3.59)Vitamin D binding protein (μg/mL)Vitamin D, *N* = 52239 ± 108323 ± 31985 (−6 to 177)12 (−88 to 111)0.816Placebo, *N* = 54258 ± 112315 ± 17354 (−4 to 112)Bioavailable 25(OH)D~3~ (nmol/L)\*^,†^Vitamin D, *N* = 506.60 (4.08--8.01)8.64 (6.57--12.0)2.25 (0.90--3.60)3.91 (2.64--5.18)\<0.001Placebo, *N* = 535.22 (3.15--8.51)4.98 (2.94--6.87)−1.30 (−2.66 to 0.05)Ratio n-oxPTH/tPTHVitamin D, *N* = 530.22 ± 0.070.23 ± 0.080.009 (−0.009 to 0.027)0.022 (0.003 to 0.042)0.027Placebo, *N* = 550.22 ± 0.060.20 ± 0.05−0.01 (−0.025 to 0.001)ADMA\*^,†^ (µmol/L)\
Vitamin D, *N* = 530.69 (0.63--0.77)0.73 (0.65--0.81)0.04 (0.01--0.07)0.008 (−0.028 to 0.045)\
0.759\
Placebo, *N* = 540.72 (0.65--0.79)0.75 (0.67--0.80)0.02 (−0.01 to 0.05)[^7][^8]

Correlation analysis was also applied to test whether the changes in several parameters before and after vitamin D supplementation in the vitamin D-treated group were correlated with ∆n-oxPTH, ∆tPTH and the ∆n-oxPTH/tPTH ratio in the vitamin D-treated group and several other parameters. These results are presented in [Table 5](#tbl5){ref-type="table"}. What is apparent from these data is that the difference in serum phosphate exhibited a significant, inverse correlation with ∆n-oxPTH, but not with ∆tPTH (rho = −0.418; *P* = 0.002; Bonferroni adjusted: *P* = 0.020 and rho = −0.314; *P* = 0.022; Bonferroni adjusted: *P* = 0.264, respectively). Also the ∆HDL correlated with ∆n-oxPTH, but not ∆tPTH (rho = 0.499; *P* \< 0.001; Bonferroni adjusted: *P* = 0.002 and rho = 0.079; *P* = 0.576; Bonferroni adjusted: *P* = 1.0, respectively). ∆n-oxPTH/tPTH ratio did not show a significant correlation with the tested parameters. Table 5Correlations for changes in n-oxPTH, PTH, n-oxPTH/tPTH ratio and changes in several parameters for the vitamin D group.Parameters∆ n-oxPTH∆ Total PTH∆ n-oxPTH/tPTH ratioSpearman's ρ*P* valueBonferroni adjusted *P*-valueSpearman's ρ*P* valueBonferroni adjusted *P* valueSpearman's ρ*P* valueBonferroni adjusted *P* value∆ n-oxPTHn.a.n.a.n.a.0.4480.0010.0100.2410.0820.988∆ 25(OH)D~3~0.0080.9581.0000.0430.7641.000−0.0160.9101.000∆ Calcium−0.3350.0140.155−0.3120.0230.2750.0510.7181.000∆ Phosphate−0.4180.0020.020−0.3140.0220.2640.0320.8211.000∆ BAP0.1170.4171.0000.0100.9441.0000.0760.5991.000∆ FGF23−0.2630.0570.631−0.1410.3151.000−0.0300.8281.000∆ ADMA0.0950.4991.000−0.0160.9081.000−0.0570.6851.000∆ LDL0.1500.2901.000−0.0390.7821.0000.0880.5331.000∆ HDL0.499\<0.0010.0020.0790.5761.0000.2160.1201.000∆ Total cholesterol0.1940.1651.000−0.1240.3771.0000.1970.1581.000

Discussion
==========

We determined the effect of vitamin D supplementation on n-oxPTH concentrations in an RCT in hypertensive vitamin D-insufficient patients with preserved kidney function and found a significant decrease in n-oxPTH concentration during supplementation. Moreover, the correlation between n-oxPTH and tPTH at baseline was only 0.555 (*P* \< 0.001), indicating large individual differences of oxidised PTH in patients with preserved renal function, as can also be seen in [Fig. 1](#fig1){ref-type="fig"}.

N-oxPTH is presumed to be the biologically active form of PTH and may reflect the hormonal activity in a more accurate way, since oxidised PTH does not activate the PTH-1 receptor ([@bib22]). Upon vitamin D treatment, both tPTH and n-oxPTH concentrations decreased. Interestingly, tPTH decreased more strongly than n-oxPTH. This resulted in a significantly increased ratio of n-oxPTH/tPTH upon supplementation. This indicates that vitamin D supplementation results in an increase in the non-oxidised fraction of PTH, or stated otherwise, that the oxidised proportion is reduced ([Fig. 2](#fig2){ref-type="fig"}). As the clinical relevance of this finding is yet to be established and the change in the n-oxPTH/tPTH ratio is small, no vast conclusions can be drawn. However, hypothetically this would implicate that vitamin D treatment leads to a reduction in the oxidation of PTH. Figure 2Vitamin D supplementation decreased tPTH and n-oxPTH, while the proportion of oxidised PTH was reduced.

Caution must be applied when interpreting this ratio. We previously published that this ratio cannot reflect the true non-oxidised percentage of the tPTH, as there is no standard for n-oxPTH yet ([@bib5]). Calculation of this ratio also showed poor agreement between several immunoassays. Although the n-oxPTH measurements are validated extensively, the ratio over tPTH, and hence, the percentage PTH that is free of oxidation, differs between several immunoassays. For this reason, we can measure n-oxPTH reliably; however, the ratio can only be used to assess changes over time.

There is a growing body of evidence about the protective effect of vitamin D on oxidative stress. Antioxidant properties of vitamin D are shown *in vitro* and *in vivo*, in rats as well as in humans ([@bib23], [@bib24], [@bib25], [@bib26]). PTH oxidation may, therefore, also be influenced by vitamin D supplementation, as is suggested by our data. However, there was no significant treatment effect on ADMA, a downstream marker of oxidative stress, in this study. ([@bib18], [@bib19])

PTH stimulates bone resorption. Osteoblasts express the PTH-1 receptor, which is activated by PTH. Once activated, osteoblasts increase their expression of RANK and inhibit the secretion of osteoprotegerin, resulting in the stimulation of osteoclast differentiation. Although PTH stimulates bone resorption, the level of PTH does not reflect bone turnover accurately. In patients with chronic kidney disease (CKD) with increasing PTH levels, the PTH concentration does not correlate well with bone turnover, based on bone histomorphometry ([@bib27]). The presumed mechanism is end-organ resistance and possibly also posttranslational oxidation of PTH ([@bib28]). In addition, a recent study showed that not only the PTH molecule, but also the PTH receptor can be oxidised ([@bib29]). In this study, Ardura *et al.* used modified PTH (1-34), where methionine residues 8 and 18 were replaced with norleucine. This way, the two residues that are prone to oxidation were stabilised. They incubated cells with H~2~O~2~ and concluded that this reduced all PTH-dependent signalling pathways. In consequence, both oxidation of the PTH molecule and the receptor could contribute to the limited correlation between PTH and bone histomorphometry in individuals with increased oxidative stress.

PTH is known to lead to decreased reabsorption of phosphate, decreased excretion of calcium and stimulation of 1-alpha-hydroxylase in the kidney. In our study, baseline concentrations of n-oxPTH and tPTH were not associated with phosphate concentrations. Interestingly, however, in the vitamin D group, the change in (∆) phosphate did not show a correlation with ∆tPTH, but did show a significant correlation with ∆n-oxPTH ([Table 5](#tbl5){ref-type="table"}). This lack of a relationship between phosphate and tPTH dynamics, in contrast to a significant relationship between phosphate and n-oxPTH dynamics may be explained by the biological activity of n-oxPTH.

N-oxPTH and tPTH did not correlate with measured bone turnover makers, which does not suggest an important role of measuring n-oxPTH for determining bone turnover in our population. Yet, the setting in our study might not be an optimal model to study these mechanisms and future studies in patients with renal failure are needed.

While some research has been carried out on the interrelation between plasma PTH and parameters of lipid metabolism, it is not completely understood. It seems that high concentrations of PTH, as seen in primary and secondary hyperparathyroidism (HPT), are accompanied by changes in parameters of lipid metabolism ([@bib30], [@bib31]). In the case of secondary HPT, these changes can be caused by many factors (e.g. the consequences of nephrotic syndrome), while in primary HPT, a more causal relationship seems plausible. Although study results are inconclusive, an improvement in lipid profile is frequently observed after parathyroidectomy in primary HPT ([@bib31], [@bib32]). The relation between HDL and n-oxPTH is of particular interest, as HDL has anti-oxidative properties ([@bib33]). It is therefore interesting that we showed in our study a significant association between the change in n-oxPTH and the change in HDL after vitamin D treatment, which was not the case for the change in tPTH. A higher HDL concentration, and hence a better antioxidant status, could explain the positive trend with n-oxPTH. A greater focus on the oxidised status of PTH could produce interesting findings that might account for inconsistencies in earlier studies on PTH and lipid metabolism.

Limitations of this study include the relatively short treatment duration of 8 weeks, the use of a specific patient group (hypertensive patients) and the small number of patients with severe vitamin D deficiency. Hypertension itself can contribute to oxidative stress, which may also increase the proportion of oxidised PTH and lower n-oxPTH concentrations ([@bib34]). Hence, the effect we observed on n-oxPTH could be an underestimation. Concerning the assessment of the correlation between n-oxPTH and bone turnover markers, our study population may not be ideal, individuals in this population are not expected to have a widely divergent rate of bone turnover. In addition, vitamin D deficiency was defined by measurements of baseline total 25(OH)D and not free 25(OH)D. Some researchers suggest that free 25(OH)D is a better marker for assessing vitamin D status ([@bib35]). Also caution of interpretation is warranted, as this is a *post hoc* analysis. Notwithstanding these limitations, the RCT design and effective vitamin D treatment as well as ample inclusion of parameters are the key strengths of the current study.

In conclusion, we showed that both tPTH and n-oxPTH decrease upon vitamin D supplementation. Our study suggests that vitamin D supplementation affects the oxidation of PTH, as we observed a small but significant increase in the non-oxidised proportion of PTH upon treatment. In addition, we found that changes in phosphate and HDL concentration showed a relationship with changes in n-oxPTH, but not tPTH. This may be explained by the biological activity of n-oxPTH. Further research should be carried out to establish the clinical relevance of n-oxPTH.
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[^2]: Data are shown as mean ± [s.d.]{.smallcaps} or median (IQR).

[^3]: \*Maximum of the two arms.

[^4]: \*Log transformed.

[^5]: \*Log transformed; ^†^Spearman's rho.

[^6]: Bioavailable 25(OH)D~3~, biologically available 25(OH)D~3~; UPCR, urinary phosphate to creatinine ratio.

[^7]: Data are shown as mean ± [s.d.]{.smallcaps} or median (IQR).

[^8]: \*Skewed variables for which transformed values were used in ANCOVA, but untransformed values are shown in the table; ^†^1 outlier was excluded; this had no effect on the significance level of the analysis.
